Skip To Main Content
Carlos H. Barrios on Muck Rack

Carlos H. Barrios

México
As seen in: MSN, MSN Mexico, MSN Venezuela, MSN Chile, Nature, Wiley Online Library, PLOS, Therapeutic Advances in Medical Oncology, MDPI, The New England Journal of Medicine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Carlos H.

Contact Carlos H., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancer

|
By François-Clément Bidard, Carlos H. Barrios, Giampaolo Bianchini, Adam Brufsky, Stephen Chia, Javier Cortés, Massimo Cristofanilli, Giuseppe Curigliano, Shaheenah Dawood, Lorenzo Gerratana, Antonio Giordano, Michail Ignatiadis, Hiroji Iwata, Wolfgang Janni, Elgene Lim, Kevin Kalinsky, Cynthia X. MA, Erica L. Mayer, Arielle Medford, Jason A. Mouabbi, Joyce O’Shaughnessy, Yeon Hee Park, Javier G. Pascual, Pedram Razavi, Sarah L. Sammons, Jose Sandoval, Luisana Sisca, Paolo Tarantino, Seth A. Wander, Gustavo Werutsky, Nicholas Turner
| Nature Verified
Introduction In patients treated with first-line AI plus CDK4/6 inhibitor, SERENA-6 showed the benefit of switching from an aromatase inhibitor to the oral SERD camizestrant upon detection of an emerging ESR1 mutation, before disease progression. While this adaptive oncology approach has shown key benefits for patients, the integration of emerging ctDNA targets into treatment decisions has been questioned.
Open in Who Shared Issue with article?

FDA Approves Vepdegestrant in ER+, HER2–, ESR1-Mutated Breast Cancer

|
By Ariana Pelosci Verified, Russ Conroy, Carlos H. Barrios
| ONCOLOGY journal Verified
The FDA has approved vepdegestrant (Veppanu) for patients with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, which is detected with an FDA-authorized test, according to a press release from the agency.1 Additionally, the FDA has approved the Guardant360 CDx as a companion diagnostic, which will help to identify patients with an ESR1 mutation.
Open in Who Shared Issue with article?

Taletrectinib Demonstrates Durable Efficacy in ROS1-Positive NSCLC

|
By Russ Conroy, Ariana Pelosci Verified, Carlos H. Barrios
| ONCOLOGY journal Verified
High, enduring response rates were observed with taletrectinib (Ibtrozi) among patients with ROS1-positive non–small cell lung cancer (NSCLC) who received no prior tyrosine kinase inhibitors (TKIs), according to a pooled analysis of the phase 2 TRUST-I (NCT04395677) and TRUST-II trials (NCT04919811) presented in a poster session at the 2026 American Association for Cancer Research (AACR) Annual Meeting.1 Lead study investigator Lyudmila Bazhenova, MD, FASCO, spoke with CancerNetwork® to break...
Open in Who Shared Issue with article?
See all 11,519 licensed articles (11,907 Total)